Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy

Chaitanya Divgi; Jorge A. Carrasquillo; Ruby Meredith; Youngho Seo; Eric C. Frey; Wesley E. Bolch; Brian E. Zimmerman; Gamal Akabani; Daniel A. Jacobson; Ben Brown; Sandra M. Davern; Robert F. Hobbs; John Humm; Eduardo G. Moros; David Morse; Rao Papineni; Pat Zanzonico; Stanley H. Benedict; George Sgouros

doi:10.1016/j.ijrobp.2020.12.002

Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy

Chaitanya Divgi, Jorge A. Carrasquillo, Ruby Meredith, Youngho Seo, Eric C. Frey, Wesley E. Bolch, Brian E. Zimmerman, Gamal Akabani, Daniel A. Jacobson, Ben Brown, Sandra M. Davern, Robert F. Hobbs, John Humm, Eduardo G. Moros, David Morse, Rao Papineni, Pat Zanzonico, Stanley H. Benedict, George Sgouros

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Radiopharmaceutical therapy (RPT) continues to demonstrate tremendous potential in improving the therapeutic gains in radiation therapy by specifically delivering radiation to tumors that can be well assessed in terms of dosimetry and imaging. Dosimetry in external beam radiation therapy is standard practice. This is not the case, however, in RPT. This NRG (acronym formed from the first letter of the 3 original groups: National Surgical Adjuvant Breast and Bowel Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group)-National Cancer Institute Working Group review describes some of the challenges to improving RPT. The main priorities for advancing the field include (1) developing and adopting best practice guidelines for incorporating patient-specific dosimetry for RPT that can be used at both large clinics with substantial resources and more modest clinics that have limited resources, (2) establishing and improving strategies for introducing new radiopharmaceuticals for clinical investigation, (3) developing approaches to address the radiophobia that is associated with the administration of radioactivity for cancer therapy, and (4) solving the financial and logistical issues of expertise and training in the developing field of RPT.

Original language	English
Pages (from-to)	905-912
Number of pages	8
Journal	International Journal of Radiation Oncology Biology Physics
Volume	109
Issue number	4
DOIs	https://doi.org/10.1016/j.ijrobp.2020.12.002
State	Published - Mar 15 2021

Funding

Disclosures: C.D. reports serving as an adviser/consultant to Janssen Inc, Invicro LLC, ReleXion Inc, and Tomopath Inc. E.C.F. reports other from Radiopharmaceutical Imaging and Dosimetry, LLC (Rapid) during the conduct of the study and other from GE Health Care outside the submitted work. R.F.H. reports personal fees from Radiopharmaceutical Imaging and Dosimetry, LLC (Rapid), outside the submitted work. In addition, R.F.H. has a patent 12/514,853 issued, a patent 12/687,670 issued, a patent 12/690,471 issued, and a patent 61/719,283 issued. R.M. is a member of the Scientific Advisory Committee of OranoMed. Y.S. reports grants from the National Cancer Institute during the conduct of the study. G.S. reports personal fees from Bayer, Inc, personal fees from Orano Med, other from Radiopharmaceutical Imaging and Dosimetry (Rapid) outside the submitted work. In addition, G.S. has a patent US 9,387,344 B2, a patent US 8,693,629 B2, and a patent US 9,757,084 B2, all licensed to Rapid. Disclosures: C.D. reports serving as an adviser/consultant to Janssen Inc, Invicro LLC, ReleXion Inc, and Tomopath Inc. E.C.F. reports other from Radiopharmaceutical Imaging and Dosimetry, LLC (Rapid) during the conduct of the study and other from GE Health Care outside the submitted work. R.F.H. reports personal fees from Radiopharmaceutical Imaging and Dosimetry, LLC (Rapid), outside the submitted work. In addition, R.F.H. has a patent 12/514,853 issued, a patent 12/687,670 issued, a patent 12/690,471 issued, and a patent 61/719,283 issued. R.M. is a member of the Scientific Advisory Committee of OranoMed. Y.S. reports grants from the National Cancer Institute during the conduct of the study. G.S. reports personal fees from Bayer, Inc, personal fees from Orano Med, other from Radiopharmaceutical Imaging and Dosimetry (Rapid) outside the submitted work. In addition, G.S. has a patent US 9,387,344 B2, a patent US 8,693,629 B2, and a patent US 9,757,084 B2, all licensed to Rapid.

Funders	Funder number
Radiopharmaceutical Imaging and Dosimetry	8,693,629 B2
Radiopharmaceutical Imaging and Dosimetry, LLC
Tomopath Inc.
National Cancer Institute	UG1CA233290
National Cancer Institute

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ijrobp.2020.12.002

Cite this

Divgi, C., Carrasquillo, J. A., Meredith, R., Seo, Y., Frey, E. C., Bolch, W. E., Zimmerman, B. E., Akabani, G., Jacobson, D. A., Brown, B., Davern, S. M., Hobbs, R. F., Humm, J., Moros, E. G., Morse, D., Papineni, R., Zanzonico, P., Benedict, S. H., & Sgouros, G. (2021). Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy. International Journal of Radiation Oncology Biology Physics, 109(4), 905-912. https://doi.org/10.1016/j.ijrobp.2020.12.002

@article{9098e633da614bf68066103c6d886773,

title = "Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy",

abstract = "Radiopharmaceutical therapy (RPT) continues to demonstrate tremendous potential in improving the therapeutic gains in radiation therapy by specifically delivering radiation to tumors that can be well assessed in terms of dosimetry and imaging. Dosimetry in external beam radiation therapy is standard practice. This is not the case, however, in RPT. This NRG (acronym formed from the first letter of the 3 original groups: National Surgical Adjuvant Breast and Bowel Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group)-National Cancer Institute Working Group review describes some of the challenges to improving RPT. The main priorities for advancing the field include (1) developing and adopting best practice guidelines for incorporating patient-specific dosimetry for RPT that can be used at both large clinics with substantial resources and more modest clinics that have limited resources, (2) establishing and improving strategies for introducing new radiopharmaceuticals for clinical investigation, (3) developing approaches to address the radiophobia that is associated with the administration of radioactivity for cancer therapy, and (4) solving the financial and logistical issues of expertise and training in the developing field of RPT.",

author = "Chaitanya Divgi and Carrasquillo, {Jorge A.} and Ruby Meredith and Youngho Seo and Frey, {Eric C.} and Bolch, {Wesley E.} and Zimmerman, {Brian E.} and Gamal Akabani and Jacobson, {Daniel A.} and Ben Brown and Davern, {Sandra M.} and Hobbs, {Robert F.} and John Humm and Moros, {Eduardo G.} and David Morse and Rao Papineni and Pat Zanzonico and Benedict, {Stanley H.} and George Sgouros",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2021",

month = mar,

day = "15",

doi = "10.1016/j.ijrobp.2020.12.002",

language = "English",

volume = "109",

pages = "905--912",

journal = "International Journal of Radiation Oncology Biology Physics",

issn = "0360-3016",

publisher = "Elsevier",

number = "4",

}

Divgi, C, Carrasquillo, JA, Meredith, R, Seo, Y, Frey, EC, Bolch, WE, Zimmerman, BE, Akabani, G, Jacobson, DA, Brown, B, Davern, SM, Hobbs, RF, Humm, J, Moros, EG, Morse, D, Papineni, R, Zanzonico, P, Benedict, SH & Sgouros, G 2021, 'Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy', International Journal of Radiation Oncology Biology Physics, vol. 109, no. 4, pp. 905-912. https://doi.org/10.1016/j.ijrobp.2020.12.002

Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy. / Divgi, Chaitanya; Carrasquillo, Jorge A.; Meredith, Ruby et al.
In: International Journal of Radiation Oncology Biology Physics, Vol. 109, No. 4, 15.03.2021, p. 905-912.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Overcoming Barriers to Radiopharmaceutical Therapy (RPT)

T2 - An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy

AU - Divgi, Chaitanya

AU - Carrasquillo, Jorge A.

AU - Meredith, Ruby

AU - Seo, Youngho

AU - Frey, Eric C.

AU - Bolch, Wesley E.

AU - Zimmerman, Brian E.

AU - Akabani, Gamal

AU - Jacobson, Daniel A.

AU - Brown, Ben

AU - Davern, Sandra M.

AU - Hobbs, Robert F.

AU - Humm, John

AU - Moros, Eduardo G.

AU - Morse, David

AU - Papineni, Rao

AU - Zanzonico, Pat

AU - Benedict, Stanley H.

AU - Sgouros, George

PY - 2021/3/15

Y1 - 2021/3/15

N2 - Radiopharmaceutical therapy (RPT) continues to demonstrate tremendous potential in improving the therapeutic gains in radiation therapy by specifically delivering radiation to tumors that can be well assessed in terms of dosimetry and imaging. Dosimetry in external beam radiation therapy is standard practice. This is not the case, however, in RPT. This NRG (acronym formed from the first letter of the 3 original groups: National Surgical Adjuvant Breast and Bowel Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group)-National Cancer Institute Working Group review describes some of the challenges to improving RPT. The main priorities for advancing the field include (1) developing and adopting best practice guidelines for incorporating patient-specific dosimetry for RPT that can be used at both large clinics with substantial resources and more modest clinics that have limited resources, (2) establishing and improving strategies for introducing new radiopharmaceuticals for clinical investigation, (3) developing approaches to address the radiophobia that is associated with the administration of radioactivity for cancer therapy, and (4) solving the financial and logistical issues of expertise and training in the developing field of RPT.

AB - Radiopharmaceutical therapy (RPT) continues to demonstrate tremendous potential in improving the therapeutic gains in radiation therapy by specifically delivering radiation to tumors that can be well assessed in terms of dosimetry and imaging. Dosimetry in external beam radiation therapy is standard practice. This is not the case, however, in RPT. This NRG (acronym formed from the first letter of the 3 original groups: National Surgical Adjuvant Breast and Bowel Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group)-National Cancer Institute Working Group review describes some of the challenges to improving RPT. The main priorities for advancing the field include (1) developing and adopting best practice guidelines for incorporating patient-specific dosimetry for RPT that can be used at both large clinics with substantial resources and more modest clinics that have limited resources, (2) establishing and improving strategies for introducing new radiopharmaceuticals for clinical investigation, (3) developing approaches to address the radiophobia that is associated with the administration of radioactivity for cancer therapy, and (4) solving the financial and logistical issues of expertise and training in the developing field of RPT.

UR - http://www.scopus.com/inward/record.url?scp=85101008598&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2020.12.002

DO - 10.1016/j.ijrobp.2020.12.002

M3 - Review article

C2 - 33309909

AN - SCOPUS:85101008598

SN - 0360-3016

VL - 109

SP - 905

EP - 912

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

IS - 4

ER -

Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this